It proved indispensable in achieving insulin independence after allogenic islet transplantation into T1D recipients, compared to no induction therapy [4,5], and was superior to daclizumab in the case of pretransplant GAD65 autoantibodies to prevent rejection, but it caused CMV viremia in simultaneous kidney and pancreas transplantation in T1D [6,7]. Here, GAD2 is linked to type 1 diabetes mellitus.